<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00212901</url>
  </required_header>
  <id_info>
    <org_study_id>2004482-01</org_study_id>
    <nct_id>NCT00212901</nct_id>
  </id_info>
  <brief_title>High Dose Ace Inhibitor Therapy Versus Combination of ACE and ARB Therapy</brief_title>
  <official_title>Addition of Angiotensin Receptor Blockade to ACE Inhibition Versus High Dose ACE Inhibition for Reduction of Proteinuria in Patients With Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <brief_summary>
    <textblock>
      Investigation of wheather addition of angiotensin receptor blocker (Irbesartan) to&#xD;
      recommended doses of angiotensin converting enzyme inhibitor (trandolapril) is more effective&#xD;
      in decreasing amount of protein in urine in patients with diabetic kidney disease than high&#xD;
      doses of trandolapril.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reducing proteinuria</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>glomerular filtration rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side-effects of hypotension, postural symptom</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetic Kidney Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose ACE-I vs ARB</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Early diabetic nephropathy as defined by proteinuria between 500mg/24hr and 3g/24hr&#xD;
             and GFR&amp;gt;50ml/min (as calculated by the Cockcroft-Gault formula), in the absence of&#xD;
             clinical and laboratory evidence of other non-diabetic renal disease.&#xD;
&#xD;
          2. Controlled blood pressure (&amp;lt;150/&amp;lt;90)&#xD;
&#xD;
          3. Able to give informed consent&#xD;
&#xD;
          4. Between the ages of 18 and 75&#xD;
&#xD;
          5. Must be capable of providing a 24 hour urine collection&#xD;
&#xD;
          6. Negative BHcG test for ruling out pregnancy in women of childbearing age&#xD;
&#xD;
          7. Currently taking an angiotensin converting enzyme inhibitor&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Creatinine clearance &amp;lt;50ml/min or 24hour protein excretion &amp;gt;3gm/d.&#xD;
&#xD;
          2. Hypotension as defined by the inability to add an ARB or increase ACE-I dose secondary&#xD;
             to hypotensive symptomatology or a systolic Bp &amp;lt;100mmHg.&#xD;
&#xD;
          3. Serum potassium &amp;gt;5.5 on two separate occasions in the previous six months&#xD;
&#xD;
          4. Previous adverse reaction to angiotensin receptor antagonist medication&#xD;
&#xD;
          5. Use of NSAIDS including COX2 inhibitors&#xD;
&#xD;
          6. Pregnant or nursing women will be excluded&#xD;
&#xD;
          7. Currently taking an angiotensin receptor antagonist&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayub Akbari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHRI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 7W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>July 25, 2007</last_update_submitted>
  <last_update_submitted_qc>July 25, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2007</last_update_posted>
  <keyword>Diabetes</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>Angiotensin converting enzyme inhibitors</keyword>
  <keyword>Angiotensin receptor antagonists</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

